Pacira BioSciences announced solid first quarter 2026 financial results with a 5% revenue increase to $177 million, driven by growth across its product portfolio including EXPAREL, ZILRETTA, and iovera°. The company highlighted successful execution of its 5x30 strategy aimed at long-term value creation, with stock up over 30% since its launch. Pacira is urging shareholders to vote for its highly qualified board nominees to prevent activist investor DOMA Perpetual from disrupting its strategic plan, which includes cost cuts and an immediate sale. The company remains confident in its growth trajectory and pipeline advancements with key clinical readouts expected later in 2026.
The FDA has granted traditional approval to Fabhalta (iptacopan), a first-in-class complement inhibitor, for slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN). Fabhalta showed a 48% slower decline in kidney fu...
Corbin Advisors' Q2 2026 survey shows industrial investor sentiment at its highest in five years, with 84% of participants bullish or neutral-to-bullish due to strong order momentum and demand from data centers and AI sectors. Expectations for Q2 rev...
CASHCAT cryptocurrency remains under strong selling pressure, unable to recover past key resistance levels between $0.125 and $0.133. The token has stabilized near $0.10 but continues to show a bearish trend with lower highs and lows since its peak a...
Cronos (CRO) surged 7.43% to $0.0597, leading gains among altcoins due to strategic partnerships and ecosystem growth. Other notable gainers included Beldex, Stable, Mantle, and Polkadot, each rising between 2% and 6%. Conversely, Lighter fell 10.43%...
Large Ethereum purchases by whales, including Arthur Hayes buying 1,293 ETH and a 21.3K ETH transfer from Fidelity Custody to a new wallet, highlight growing institutional confidence despite ETH trading below $2,000. Exchange data shows mixed short-t...
